Moderna claims its scientists alone invented the mRNA sequence used to produce its COVID-19 vaccine. The US government, which helped fund the drug, disagrees.
Academic rigor, journalistic flair
Articles on mRNA
Displaying 21 - 40 of 50 articles
Afrigen will be a technology transfer and training hub: it shares technology and develops skills specifically around how to produce a safe, effective and affordable mRNA vaccine.
But the immune cells that vaccination spurs do last a long time.
An FDA panel has voted against recommending approval of a booster COVID-19 shot for the general population – disappointing some public health officials.
Thanks to the collaborative efforts of governments, funding agencies, academia, biotech and pharmaceutical companies, large-scale manufacturing of mRNA drug products is becoming a reality.
An infectious disease doctor explains the science behind COVID-19 vaccines at a level that children – and adults – of all ages can understand.
As many teens and adults in the US restart their social lives, parents of children under the age of 12 wonder when their kids will also be able to experience the freedom that comes with vaccination.
This myth is still circulating online. Here’s why the chance of this happening is next to zero.
A vaccine expert breaks down everything you need to know about Australia’s newest COVID-19 vaccine candidate.
Canadian public health organizations have run into a serious communication problem about the AstraZeneca vaccine. Crisis management and communication theories explain what’s gone wrong.
Skyrocketing demand coupled with shortages of vital components is leading to bottlenecks in the supply chain of Pfizer’s and other mRNA vaccines.
We have two mRNA COVID-19 vaccines so far. But what else can this technology do?
With changing recommendations about AstraZeneca’s COVID-19 vaccine making headlines, many people have questions about its use.
In the spotlight for its role in COVID-19 vaccines – and a Nobel Prize – mRNA is not a new invention. It’s a crucial messenger molecule at work every day in every cell in your body.
RNA was used to make COVID vaccines. Now it could lead to more personalised healthcare.
So far, most vaccines in the US are mRNA vaccines. These represent a new technology and are likely to take over the vaccine world. But how do they work? What are their weaknesses? Five experts explain.
The coronavirus pandemic has driven a lot of scientific progress in the past year. But just as some of the social changes are likely here to stay, so are some medical innovations.
With the vaccines now being administered at sites around the US, it is important to address misinformation surrounding the effort.
Researchers are already working to improve the current crop of mRNA vaccines. Hopefully this will help them become more practical and affordable for the entire world, not just first-world countries.
With slow vaccine distribution and manufacturing, some people won’t get the second dose on time. But does it matter?
Top contributors
-
Research associate, Warren Alpert Medical School, Brown University, Brown University
-
Professor of Pathology, Microbiology and Immunology, University of South Carolina
-
Professor of Microbiology, School of Medicine, University of Washington
-
Associate Professor and ARC Future Fellow, The University of Western Australia
-
Professor of Pathology, Microbiology and Immunology, University of South Carolina
-
Professor of Medicine, University of Virginia
-
Postdoctoral Research Fellow, RNA Biology and Biochemistry, Brighton and Sussex Medical School
-
Pediatric Infectious Diseases Fellow, University of Pittsburgh
-
Clinical Associate Professor of Pharmacy Practice, Binghamton University, State University of New York
-
Early Career Research Leader, Emerging Viruses, Inflammation and Therapeutics Group, Menzies Health Institute Queensland, Griffith University
-
Professor and Department Chair of Infectious Diseases and Microbiology, University of Pittsburgh
-
Vice-Chancellor's Research Fellow, School of Health and Biomedical Sciences, RMIT University
-
Professor of virology and theme leader for viral infectious diseases, The Peter Doherty Institute for Infection and Immunity
-
Senior Lecturer; MD, Victoria University
-
Professor and Director of Quantitative Biosciences Institute & Senior Investigator at the Gladstone Institutes, University of California, San Francisco
